Skip to main content

Table 3 Baseline characteristics

From: Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis

StudiesAgeMalesT2DMHTNSmokingDYS
TC/NTCTC/NTCTC/NTCTC/NTCTC/NTCTC/NTC
Ayoub 2018 [8]68.8/69.373.1/73.945.9/46.977.1/77.9
Ito 2018 [9]71.8/68.079.5/72.944.4/39.681.5/81.821.2/28.639.7/42.3
Kiviniemi 2013 [10]74.0/73.085.0/68.031.0/37.076.0/85.06.00/11.069.0/66.0
Liu 2018 [11]60.9/57.913.5/24.535.2/29.360.9/64.859.3/56.265.5/67.5
Overgaard 2008 [12]67.0/63.084.5/71.532.2/26.961.7/61.346.0/38.0
Raphael 2016 [13]70.6/67.482.0/71.044.0/30.085.0/80.084.0/85.0
Shiraishi 2019 [14]74.0/72.074.8/73.453./43.877.4/75.911.9/16.260.6/66.5
Yadav 2016 [15]65.7/61.987.3/73.832.0/23.567.7/61.126.9/36.057.9/51.5
  1. Abbreviations: T2DM type 2 diabetes mellitus, HTN hypertension, DYS dyslipidemia, TC thrombocytopenia group, NTC non-thrombocytopenia group